Evidence map›Paper›PMID 36786604›Full record

ArticlemBio2023

High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020.

Shuting Zhang, Peijun Ma, Marek Orzechowski, Allison Lemmer, Kara Rzasa, Josephine Bagnall, Sulyman Barkho, Michael Chen, Lorri He, Raymond Neitupski and 20 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Serologic Evidence for Early SARS-CoV-2 Circulation in Lima, Peru, 2020.The American journal of tropical medicine and hygiene · 2024
    Article
  5. Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 4 institutions in 1 country.

Shuting ZhangBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Peijun MaBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Marek OrzechowskiBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Allison LemmerBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Kara RzasaBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Josephine BagnallBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Sulyman BarkhoBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Michael ChenBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Lorri HeBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Raymond NeitupskiBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Victoria TranBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Ross AckermanBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Emily GathBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Austin BondBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Giana FrongilloBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Thomas ClelandBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Aaron GolasBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Anthony GacaBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Michael FitzgeraldBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Kathleen KellyVitalant Research Institute, Denver, Colorado, USA.
Kelsey HazeghVitalant Research Institute, Denver, Colorado, USA.
Larry DumontVitalant Research Institute, Denver, Colorado, USA.
Corey HoffmanBiomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, Department of Health and Human Services, Washington, DC, USA.
Mary HomerBiomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, Department of Health and Human Services, Washington, DC, USA.ORCID 0000-0003-4895-7672
Peter MarksCenter for Biologics Evaluation and Research, US FDA, Silver Spring, Maryland, USA.
Ann WoolleyBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Sharon WongBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
James GomezBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Jonathan LivnyBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Deborah HungBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.ORCID 0000-0003-4262-0673
Broad Institute · USVitalant · USBiomedical Advanced Research and Development Authority · USCenter for Biologics Evaluation and Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ability to measure neutralizing antibodies on large scale can be important for understanding features of the natural history and epidemiology of infection, as well as an aid in determining the efficacy of interventions, particularly in outbreaks such as the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Because of the assay's rapid scalability and high efficiency, serology measurements that quantify the presence rather than function of serum antibodies often serve as proxies of immune protection. Here, we report the development of a high-throughput, automated fluorescence-based neutralization assay using SARS-CoV-2 virus to quantify neutralizing antibody activity in patient specimens. We performed large-scale testing of over 19,000 COVID-19 convalescent plasma (CCP) samples from patients who had been infected with SARS-CoV-2 between March and August 2020 across the United States. The neutralization capacity of the samples was moderately correlated with serological measurements of anti-receptor-binding domain (RBD) IgG levels. The neutralizing antibody levels within these convalescent-phase serum samples were highly variable against the original USA-WA1/2020 strain with almost 10% of individuals who had had PCR-confirmed SARS-CoV-2 infection having no detectable antibodies either by serology or neutralization, and ~1/3 having no or low neutralizing activity. Discordance between neutralization and serology measurements was mainly due to the presence of non-IgG RBD isotypes. Meanwhile, natural infection with the earliest SARS-CoV-2 strain USA-WA1/2020 resulted in weaker neutralization of subsequent B.1.1.7 (alpha) and the B.1.351 (beta) variants, with 88% of samples having no activity against the BA.1 (omicron) variant.

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralCOVID-19 SerotherapyCOVID-19 TestingHumansImmunity, HumoralNeutralization TestsSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2neutralizing antibodiesSARS-CoV-2serology

Identifiers

PMID36786604
PMCPMC10128039
OpenAlexW4320710441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.